BridgeBio Pharma (BBIO) Current Assets (2018 - 2026)

BridgeBio Pharma (BBIO) has 9 years of Current Assets data on file, last reported at $1.2 billion in Q1 2026.

• For the quarter ending Q1 2026, Current Assets rose 78.56% year-over-year to $1.2 billion; the trailing twelve-month figure through Mar 2026 stood at $1.2 billion (up 78.56% YoY), and the FY2025 full-year result was $797.7 million, up 10.69% from the prior year.
• Current Assets grew to $1.2 billion in Q1 2026, from $797.7 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $1.2 billion in Q1 2026 to a low of $432.9 million in Q2 2023.
• A 5-year average of $693.0 million and a median of $695.2 million in 2025 frame the typical range for Current Assets.
• Across the five-year window, Current Assets plunged 43.87% in 2023 and surged 88.8% in 2025, its largest moves.
• Tracing BBIO's Current Assets over 5 years: stood at $548.9 million in 2022, then declined by 12.98% to $477.6 million in 2023, then surged by 50.9% to $720.7 million in 2024, then grew by 10.69% to $797.7 million in 2025, then surged by 55.6% to $1.2 billion in 2026.
• Business Quant data shows BBIO's Current Assets at $1.2 billion in Q1 2026, $797.7 million in Q4 2025, and $839.4 million in Q3 2025.